Table 1.
Model including age | Adjusted OR (95% CI) for under-dosing | P-valueb | Adjusted OR (95% CI) for over-dosing | P-valueb |
---|---|---|---|---|
Patient age (years) | 1.03 (1.02 to 1.05) | <0.001 | 1.05 (0.99 to 1.10) | 0.084 |
| ||||
DOAC molecule | <0.001 | 0.223 | ||
Apixaban | 3.93 (2.29 to 6.74) | 3.14 (0.82 to 12.06) | ||
Dabigatran | 1.55 (1.17 to 2.06) | 1.02 (0.43 to 2.42) | ||
Rivaroxaban | 1 (ref) | 1 (ref) | ||
| ||||
Kidney function (Cockcroft–Gault) (ml/min) | 0.002 | 0.010 | ||
Normal, ≥60 | 1 (ref) | 1 (ref) | ||
Moderate/severe/terminal failure, <60 | 0.59 (0.42 to 0.83) | 3.28 (1.34 to 8.08) |
Akaike information criterion = 1455.14; Bayesian information criterion =1504.42.
Adjusted P-value for all the reported variables, obtained from the Wald test using multinomial multivariate logistic regression. CI = confidence interval. DOAC = direct oral anticoagulant. OR = odds ratio.